NCT05362149 - An Observational Study, Called DEAR, to Learn More About Treatment With Darolutamide, Enzalutamide and Apalutamide in Men With Non-metastatic Castration-resistant Prostate Cancer in Real World Settings | Biotech Hunter

Enrollment

870

Participants

Timeline

Start Date

April 4, 2022

Primary Completion Date

June 30, 2023

Study Completion Date

June 30, 2023

Conditions

Non-metastatic Castration-resistant Prostate Cancer

Interventions

DRUG

Darolutamide (Nubeqa, BAY1841788)

Retrospective cohort analysis, using PPS EMR prostate cancer database in the US.

DRUG

Enzalutamide

Retrospective cohort analysis, using PPS EMR prostate cancer database in the US.

DRUG

Apalutamide

Retrospective cohort analysis, using PPS EMR prostate cancer database in the US.

Trial Locations (1)

Bayer, Whippany